ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NSRT to start Phase II trial of Eflornithine granules to treat COVID-19 by early Jan 2021
January 04, 2021Mumbai-based Navin Saxena Research & Technology (NSRT) plans to start Phase II clinical trial of Eflornithine granules 2.5 gm for the treatment of moderate COVID-19 infection by the first week of January 2021. -
NSRT to conduct phase II trials of Eflornithine to treat COVID-19
November 19, 2020The trials will be conducted in four cities namely; Delhi, Lucknow, Pune, and Bengaluru and the company aims to complete the study in three to four months.
Pharma Sources Insight January 2025
